The University of Texas MD Anderson Cancer Center and RUSH University System for Health today announced a partnership to create RUSH MD Anderson Cancer Center.
RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, have announced that Eileen White, PhD, Deputy Director and Chief Scientific Officer at Rutgers Cancer Institute, has been elected as a member of the American Academy of Arts and Sciences.
The Foundation for the Accreditation of Cellular Therapy (FACT) has once again awarded Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital’s (RWJUH) Transplant and Cell Therapy Program accreditation under the FACT-JACIE International Standards for Hematopoietic Cellular Therapy
Cells constantly navigate a dynamic environment, facing ever-changing conditions and challenges. But how do cells swiftly adapt to these environmental fluctuations? A new Moffitt Cancer Center study, published in iScience, is answering that question by challenging our understanding of how cells function. A team of researchers suggests that cells possess a previously unknown information processing system that allows them to make rapid decisions independent of their genes.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
A Ludwig Cancer Research study has discovered how a lipid molecule found at high levels within tumors undermines the anti-cancer immune response and compromises a recently approved immunotherapy known as adoptive cell therapy (ACT) using tumor infiltrating lymphocytes, or TIL-ACT.
Dana-Farber Cancer Institute nurse scientists and clinicians are presenting key studies and projects at the 49th annual Oncology Nursing Society (ONS) Congress on April 24-28, 2024, in Washington, D.C.
Socioeconomic factors are preventing some patients from accessing common treatment to stop progression of multiple myeloma.
New study by UC Davis researchers shows how pharmacies may provide crucial access to tobacco cessation tools that help people successfully quit smoking.
In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have designed a new method for developing immunotherapy drugs using engineered peptides to elicit a natural immune response inside the body.
Kevin Haigis, PhD, Chief Scientific Officer, Dana-Farber Cancer Institute, has been named Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is a distinguished lifetime honor bestowed upon AAAS members by their peers.
A new Moffitt Cancer Center study published in the journal Immunity offers insight into how lung cancer cells evade the protective immune system, potentially opening a door for novel antibody-based immunotherapies. Their study centers on a molecule called Jagged2, which plays a primary role in fueling the aggressiveness and immune evasion capacity of lung cancer.
In recognition of their significant achievements in the realm of cancer care and research, four researchers at The University of Texas MD Anderson Cancer Center have been elected fellows of the American Association for the Advancement of Science (AAAS). This prestigious distinction stands as one of the highest accolades within the scientific research community.
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—announces 2024 award recipients that include individuals and groups who have made significant and noteworthy impacts on improving cancer care and supporting NCCN’s mission to help all people with cancer to live better lives.
New research in the April 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer.
Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone.
For the study, which involved patients from across the world, Yale Cancer Center (YCC) researchers at Yale School of Medicine (YSM) analyzed the genetic landscape of 66 tumors, the largest series of cervical NET ever reported in scientific literature.
MD Anderson and CureVac today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
The National Comprehensive Cancer Network (NCCN) and the NCCN Foundation announce five winners for the 2024 NCCN Foundation Young Investigator Awards (YIA).
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
A new study from UC Davis Health's Emergency Medicine may lead to a reduction in inappropriate computed tomography use in injured children.
More than 1,700 oncology professionals attended National Comprehensive Cancer Network meeting in Orlando and online, featuring clinical and administrative updates for improving cancer care worldwide, plenary sessions on Lynch syndrome and drug shortages, plus nearly 200 poster abstracts with new research.
Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.
Cervical cancer, often caused by persistent human papillomavirus (HPV) infections, remains a public health challenge worldwide despite falling diagnoses related to the success of the HPV vaccine[GR1] in young adult women.
UC Davis Medical Center has become the first hospital in Western U.S. to perform a successful transcatheter tricuspid valve repair procedure with a groundbreaking catheter.
Obesity is associated with a higher risk of developing at least 13 types of cancer — and worse outcomes after diagnosis. But lung cancer seems to be an exception: Studies have shown that patients with a high body mass index (BMI) experience a lower risk of disease recurrence and longer survival after surgical treatment — an irregularity called “the obesity paradox.”
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results from the Phase I/II KRYSTAL-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Jeffrey A. Drebin, MD, PhD, has been named President-Elect of the American Surgical Association (ASA) for 2024.
The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings today from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association for Cancer Research (AACR) Annual Meeting 2024.
In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer. In this study, tumors were reduced in six out of 16 patients treated with the combination, including one case in which the cancer disappeared.
Numerous studies conducted by researchers at Dana-Farber Cancer Institute show promising results for patients with endometrial, lung, breast, prostate, and colorectal cancers.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Researchers at The University of Texas MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays and improved patient satisfaction.
The Advanced Psychiatric Therapeutics Clinic offers esketamine and transcranial magnetic stimulation (TMS) for patients with treatment-resistant depression.
Two researchers from The University of Texas MD Anderson Cancer Center will be honored with Scientific Achievement Awards at the American Association for Cancer Research (AACR) Annual Meeting 2024 for accomplishments in clinical and translational research as well as outstanding leadership in oncology.
A new study published April 4 in Cancer Cell was led by Yale Cancer Center researchers, who collaborated with investigators nationally to differentiate the molecular subgroups of RCC tumors to better understand how their makeup might affect treatment responses.
SEATTLE — April 3, 2024 — Below are summaries of recent Fred Hutchinson Cancer Center research findings, patient stories and other news. If you’re covering the American Association for Cancer Research (AACR) Annual Meeting, please see our list of and contact to set up interviews.
Padmanee Sharma, M.D., Ph.D., associate vice president of Immunobiology, professor of Genitourinary Medical Oncology and Immunology, and director of scientific programs for the James P. Allison Institute at The University of Texas MD Anderson Cancer Center, has been elected to the 2024 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of her work to establish and advance immune checkpoint therapies as effective treatments for patients with a variety of cancers.
Researchers from Fred Hutchinson Cancer Center, the American Cancer Society Cancer Action Network and peer institutions released new findings in the Journal of Clinical Oncology showing that when all types of cancer research studies are considered, at least one in five people with cancer in the U.S., or 21.9%, participate in some form of clinical research.
Moffitt Cancer Center announced today a collaboration with NVIDIA, Oracle and Deloitte* on an initiative aimed at revolutionizing cancer care delivery through advanced artificial intelligence and machine learning technologies.
Staring at the sun can damage your eyes in less than a minute. An ophthalmologist explains how to protect your vision during the 2024 eclipse.
The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress. Revolutionizing Care,” will include new findings from Yale Cancer Center researchers.
Benyi Li, MD, PhD, professor in the Department of Urology and member of The University of Kansas Cancer Center, has received a nearly $1.4 million grant from the U.S. Department of Defense to develop a short peptide-based therapy for prostate cancer patients.
Dana-Farber Cancer Institute has implemented an artificial intelligence (AI) application intended for general use in a medical center or hospital.
In a survey of more than 200 U.S. oncologists, vast majority indicate that oncologists should be able to explain how AI works to their patients. Respondents say AI developers, more than oncologists or hospitals, have responsibility for legal issues arising from AI use in cancer care.
Andrew E. Place, MD, PhD, has been named as Vice President, Pediatric Chief Medical Officer (CMO) at Dana-Farber Cancer Institute (within the Department of Pediatric Oncology) and Boston Children’s Hospital (within the Division of Hematology/Oncology) for the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
UC Davis Health received a $3 million grant to support research by the Black & Brown Collective. The group is studying gun violence that disproportionately impacts marginalized communities.
The American Society of Clinical Oncology (ASCO) recognized Janet L. Abrahm, MD, FACP, FAAHPM, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, as a recipient of an ASCO Special Award, the Society’s highest honor.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
